By Associate Professor Meg Jardine

Journal articles

Talbot B; Cass A; Walker R; Hooi L; Jardine M; Jun M; Rogers K; Sukkar L; Smyth B; Gallagher M, 2023, 'Comparing survival in patients with chronic kidney disease across three countries – Results from the study of heart and renal protection-extended review', Nephrology, 28, pp. 36 - 43, http://dx.doi.org/10.1111/nep.14127

Xie Y; Lin J; Gallagher M; Bellomo R; Wang X; Jardine M; Duan M; Wang A, 2023, 'Prognostic Significance of Baseline Blood Glucose Levels and Glucose Variability in Severe Acute Kidney Injury: A Secondary Analysis from the RENAL Study', Journal of Clinical Medicine, 12, http://dx.doi.org/10.3390/jcm12010015

Jain SS; Yu J; Arnott C; Neal B; Perkovic V; Neuen BL; Jardine M; Mahaffey KW, 2023, 'Treatment effect of canagliflozin for patients on therapy for heart failure: Pooled analysis of the CANVAS program and CREDENCE trial', International Journal of Cardiology, 395, http://dx.doi.org/10.1016/j.ijcard.2023.131444

Koshino A; Neuen BL; Oshima M; Toyama T; Hara A; Arnott CG; Neal B; Jardine M; Badve S; Mahaffey KW; Pollock CA; Hansen MK; Wada T; Heerspink HJ, 2023, 'Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients with Type 2 Diabetes and CKD: A Post Hoc Analysis of the CREDENCE Trial', Journal of the American Society of Nephrology, 34, pp. 140 - 140, http://dx.doi.org/10.1681/asn.20233411s1140b

Koshino A; Neuen BL; Arnott CG; Neal B; Jardine M; Badve S; Mahaffey KW; Pollock CA; Hansen MK; Wada T; Heerspink HJ, 2023, 'Iron Biomarkers and Effects of Canagliflozin in Patients with Type 2 Diabetes and CKD: A Post Hoc Analysis of the CREDENCE Trial', Journal of the American Society of Nephrology, 34, pp. 140 - 140, http://dx.doi.org/10.1681/asn.20233411s1140c

Jun M; Wick J; Neuen BL; Kotwal SS; Badve S; Chalmers JP; Jardine M; Perkovic V; Gallagher MP; Ronksley PE, 2023, 'The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset', Journal of the American Society of Nephrology, 34, pp. 373 - 373, http://dx.doi.org/10.1681/asn.20233411s1373a

Jain SS; Yu J; Arnott C; Neal BC; Perkovic V; Neuen B; Jardine M; Mahaffey KW, 2023, 'TREATMENT EFFECT OF CANAGLIFLOZIN FOR PATIENTS ON THERAPY FOR HEART FAILURE: POOLED ANALYSIS OF THE CANVAS PROGRAM AND CREDENCE TRIAL', Journal of the American College of Cardiology, 81, pp. 283, http://dx.doi.org/10.1016/s0735-1097(23)00727-1

TALBOT B; Davies S; Burman J; Ritchie A; Snelling P; Lynch S; Park Y; Jones B; Garvey V; Jaure A; Jardine M; Perkovic V; Gallagher M; Brandwood A; Knight J, 2023, 'WCN23-0574 THE ELLEN MEDICAL DEVICES AFFORDABLE POINT-OF-CARE PERITONEAL DIALYSIS SYSTEM - A PILOT STUDY', Kidney International Reports, 8, pp. S350 - S350, http://dx.doi.org/10.1016/j.ekir.2023.02.786

Lambers Heerspink H; Jardine M; Kohan DE; Lafayette R; Levin A; Liew A; Zhang H; Sheth K; Camargo M; Jones-Burton C; King AJ; Barratt J, 2023, 'WCN23-1085 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATY- THE ALIGN STUDY', Kidney International Reports, 8, pp. S279 - S280, http://dx.doi.org/10.1016/j.ekir.2023.02.630

Nunes JC; Yu J; Arnott C; Jardine MJ; Perkovic V; Mahaffey KW, 2022, 'Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program', Diabetes, Obesity and Metabolism, 24, pp. 2459 - 2464, http://dx.doi.org/10.1111/dom.14832

McGree JM; Hockham C; Kotwal S; Wilcox A; Bassi A; Pollock C; Burrell LM; Snelling T; Jha V; Jardine M; Jones M, 2022, 'Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial', Trials, 23, pp. 361, http://dx.doi.org/10.1186/s13063-022-06167-2

O'Hara DV; Yi TW; Lee VW; Jardine M; Dawson J, 2022, 'Digital health technologies to support medication adherence in chronic kidney disease', Nephrology, 27, pp. 917 - 924, http://dx.doi.org/10.1111/nep.14113

Viecelli AK; Teixeira-Pinto A; Valks A; Baer R; Cherian R; Cippà PE; Craig JC; DeSilva R; Jaure A; Johnson DW; Kiriwandeniya C; Kopperschmidt P; Liu WJ; Lee T; Lok C; Madhan K; Mallard AR; Oliver V; Polkinghorne KR; Quinn RR; Reidlinger D; Roberts M; Sautenet B; Hooi LS; Smith R; Snoeijs M; Tordoir J; Vachharajani TJ; Vanholder R; Vergara LA; Wilkie M; Yang B; Yuo TH; Zou L; Hawley CM; Robison L; Welch A; Badve SV; Boudville N; Campbell K; Cho Y; Collins M; Fahim MA; Jardine M; Du Toit D; Mayne M; Stevenson K; James R; Vu Q; Allen K; Glancy L; Kumbikkal J; Burton S; Gordon L; McCarthy K; Forrester C; Lima S; Bourgault O; Drouault C; Teasdale F; Jiun LW; Abidin J; Kiang CJ; Leng LS; Yusoff YM; Ciochina A; van Loon M; Ophelders R; Vleugels MJ; Ferrari P; Brodeur MÈ; Giunzioni D; Molfese CB; Blackwell C; Dunn L; Gillis L; Gray B; Jenkins S, 2022, 'Study protocol for Vascular Access outcome measure for function: a vaLidation study In hemoDialysis (VALID): A multi-center, multinational validation study to assess the accuracy and feasibility of measuring vascular access function in clinical practice', BMC Nephrology, 23, http://dx.doi.org/10.1186/s12882-022-02987-1

Baigent C; Emberson JR; Haynes R; Herrington WG; Judge P; Landray MJ; Mayne KJ; Ng SYA; Preiss D; Roddick AJ; Staplin N; Zhu D; Anker SD; Bhatt DL; Brueckmann M; Butler J; Cherney DZI; Green JB; Hauske SJ; Heerspink HJL; Inzucchi SE; Jardine MJ; Liu CC; Mahaffey KW; McCausland FR; McGuire DK; McMurray JJV; Neal B; Neuen BL; Packer M; Perkovic V; Sabatine MS; Solomon SD; Vaduganathan M; Wanner C; Wheeler DC; Wiviott SD; Zannad F, 2022, 'Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials', The Lancet, 400, pp. 1788 - 1801, http://dx.doi.org/10.1016/S0140-6736(22)02074-8

Sarraju A; Bakris G; Cannon CP; Cherney D; Damaraju CV; Figtree GA; Gogate J; Greene T; Heerspink HJL; Januzzi JL; Neal B; Jardine MJ; Blais J; Kosiborod M; Levin A; Lingvay I; Weir MR; Perkovic V; Mahaffey KW, 2022, 'Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria', Journal of the American College of Cardiology, 80, pp. 1721 - 1731, http://dx.doi.org/10.1016/j.jacc.2022.08.772

Li JW; Arnott C; Heerspink HJL; Mbiostat QL; Cannon CP; Wheeler DC; Charytan DM; Barraclough J; Figtree GA; Agarwal R; Bakris G; de Zeeuw D; Greene T; Levin A; Pollock C; Zhang H; Zinman B; Mahaffey KW; Perkovic V; Neal B; Jardine MJ, 2022, 'Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial', Journal of the American Heart Association, 11, pp. e025045, http://dx.doi.org/10.1161/JAHA.121.025045

Neuen BL; Jardine MJ, 2022, 'SGLT2 inhibitors and finerenone: one or the other or both?', Nephrology Dialysis Transplantation, 37, pp. 1209 - 1211, http://dx.doi.org/10.1093/ndt/gfac046

Liao J; Kang A; Xia C; Young T; Di Tanna GL; Arnott C; Pollock C; Krishnan AV; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Heerspink HJL; Levin A; Neal B; Wheeler DC; Zhang H; Zinman B; Mahaffey KW; Perkovic V; Jardine MJ; Smyth B, 2022, 'The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial', Diabetes and Metabolism, 48, pp. 101331, http://dx.doi.org/10.1016/j.diabet.2022.101331

Hockham C; Bao L; Tiku A; Badve SV; Bello AK; Jardine MJ; Jha V; Toyama T; Woodward M; Jun M, 2022, 'Sex differences in chronic kidney disease prevalence in Asia: A systematic review and meta-analysis', Clinical Kidney Journal, 15, pp. 1144 - 1151, http://dx.doi.org/10.1093/ckj/sfac030

Gallagher A; Agresta B; Smyth B; Jardine M; Ferro C; Morton RL, 2022, 'Trimming the fat: Is there a health economic case for the use of new lipid-lowering drugs in chronic kidney disease? A scoping review', Clinical Kidney Journal, 15, pp. 1049 - 1059, http://dx.doi.org/10.1093/ckj/sfab288

Lv J; Wong MG; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Zhao M; Barbour S; Jardine MJ; Reich HN; Cattran D; Glassock R; Levin A; Wheeler DC; Woodward M; Billot L; Stepien S; Rogers K; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Zhang H; Perkovic V, 2022, 'Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial', JAMA - Journal of the American Medical Association, 327, pp. 1888 - 1898, http://dx.doi.org/10.1001/jama.2022.5368

Kang A; Sukkar L; Hockham C; Jun M; Young T; Scaria A; Foote C; Neuen BL; Cass A; Pollock C; Comino E; Lung T; Pecoits-Filho R; Rogers K; Jardine MJ; Chow C; Gallagher M; Jan S; Knight J; Liu B; McNamara M; Peiris D; Ssullivan D; Wong G; Zoungas S; Wilson R, 2022, 'Risk factors for incident kidney disease in older adults: an Australian prospective population-based study', Internal Medicine Journal, 52, pp. 808 - 817, http://dx.doi.org/10.1111/imj.15074

Feng Y; Li Q; Finfer S; Myburgh J; Bellomo R; Perkovic V; Jardine M; Wang AY; Gallagher M, 2022, 'A Novel Risk Prediction Model for Severe Acute Kidney Injury in Intensive Care Unit Patients Receiving Fluid Resuscitation', Frontiers in Cardiovascular Medicine, 9, http://dx.doi.org/10.3389/fcvm.2022.840611

Fu EL; Clase CM; Janse RJ; Lindholm B; Dekker FW; Jardine MJ; Carrero JJ, 2022, 'Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice', International Journal of Cardiology, 352, pp. 172 - 179, http://dx.doi.org/10.1016/j.ijcard.2022.01.042

Yi TW; Laing C; Kretzler M; Nkulikiyinka R; Legrand M; Jardine M; Rossignol P; Smyth B, 2022, 'Digital health and artificial intelligence in kidney research: A report from the 2020 Kidney Disease Clinical Trialists (KDCT) meeting', Nephrology Dialysis Transplantation, 37, pp. 620 - 627, http://dx.doi.org/10.1093/ndt/gfab320

Vinson AJ; Singh S; Chadban S; Cherney D; Gaber O; Gill JS; Helgeson E; Herzog CA; Jardine M; Jha V; Kasiske BL; Mannon RB; Michos ED; Mottl AK; Newby K; Roy-Chaudhury P; Sawinski D; Sharif A; Sridhar VS; Tuttle KR; Vock DM; Matas A, 2022, 'Premature Death in Kidney Transplant Recipients: The Time for Trials is Now', Journal of the American Society of Nephrology, 33, pp. 665 - 673, http://dx.doi.org/10.1681/ASN.2021111517

O’Hara DV; Jardine MJ, 2022, 'SGLT2 inhibitors may prevent diabetes', Nature Reviews Nephrology, 18, pp. 203 - 204, http://dx.doi.org/10.1038/s41581-022-00541-8

Campain A; Hockham C; Sukkar L; Rogers K; Chow CK; Lung T; Jun M; Pollock C; Cass A; Sullivan D; Comino E; Peiris D; Jardine M, 2022, 'Prior Cardiovascular Treatments—A Key Characteristic in Determining Medication Adherence After an Acute Myocardial Infarction', Frontiers in Pharmacology, 13, http://dx.doi.org/10.3389/fphar.2022.834898

Charytan DM; Yu J; Jardine MJ; Cannon CP; Agarwal R; Bakris G; Greene T; Levin A; Pollock C; Powe NR; Arnott C; Mahaffey KW, 2022, 'Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial', Clinical Journal of the American Society of Nephrology, 17, pp. 361 - 373, http://dx.doi.org/10.2215/CJN.08980621

Natale P; Palmer SC; Saglimbene VM; Ruospo M; Razavian M; Craig JC; Jardine MJ; Webster AC; Strippoli GFM, 2022, 'Antiplatelet agents for chronic kidney disease', Cochrane Database of Systematic Reviews, 2022, http://dx.doi.org/10.1002/14651858.CD008834.pub4

Heerspink HJL; Oshima M; Zhang H; Li J; Agarwal R; Capuano G; Charytan DM; Craig J; de Zeeuw D; Di Tanna GL; Levin A; Neal B; Perkovic V; Wheeler DC; Yavin Y; Jardine MJ, 2022, 'Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial', American Journal of Kidney Diseases, 79, pp. 244 - 256.e1, http://dx.doi.org/10.1053/j.ajkd.2021.05.005

Xu Y; Fu EL; Clase CM; Mazhar F; Jardine MJ; Carrero JJ, 2022, 'GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes', Kidney International, 101, pp. 360 - 368, http://dx.doi.org/10.1016/j.kint.2021.10.033

Jardine MJ; Kotwal SS; Bassi A; Hockham C; Jones M; Wilcox A; Pollock C; Burrell LM; McGree J; Rathore V; Jenkins CR; Gupta L; Ritchie A; Bangi A; D'Cruz S; McLachlan AJ; Finfer S; Cummins MM; Snelling T; Jha V, 2022, 'Angiotensin receptor blockers for the treatment of covid-19: Pragmatic, adaptive, multicentre, phase 3, randomised controlled trial', BMJ, 379, pp. e072175, http://dx.doi.org/10.1136/bmj-2022-072175

Clase CM; Dicks E; Holden R; Sood MM; Levin A; Kalantar-Zadeh K; Moore LW; Bartlett SJ; Bello AK; Bohm C; Bridgewater D; Bouchard J; Burger D; Carrero JJ; Donald M; Elliott M; Goldenberg MJ; Jardine M; Lam NN; Maddigan WJ; Madore F; Mavrakanas TA; Molnar AO; Prasad GVR; Rigatto C; Tennankore KK; Torban E; Trainor L; White CA; Hartwig S, 2022, 'Can Peer Review Be Kinder? Supportive Peer Review: A Re-Commitment to Kindness and a Call to Action', Canadian Journal of Kidney Health and Disease, 9, http://dx.doi.org/10.1177/20543581221080327

Yi TW; Atiquzzaman M; Zheng Y; Smyth B; Jardine M; Levin A, 2022, 'Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study', Canadian Journal of Kidney Health and Disease, 9, http://dx.doi.org/10.1177/20543581221145068

Wada T; Mori-Anai K; Kawaguchi Y; Katsumata H; Tsuda H; Iida M; Arakawa K; Jardine MJ, 2022, 'Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial', Journal of Diabetes Investigation, 13, pp. 54 - 64, http://dx.doi.org/10.1111/jdi.13624

Young TK; Toussaint ND; Di Tanna GL; Arnott C; Hockham C; Kang A; Schutte AE; Perkovic V; Mahaffey KW; Agarwal R; Bakris GL; Charytan DM; Heerspink HJL; Levin A; Pollock C; Wheeler DC; Zhang H; Jardine MJ, 2022, 'Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial', Journal of Diabetes Research, 2022, http://dx.doi.org/10.1155/2022/9998891

Januzzi JL; Butler J; Sattar N; Tefera E; Rosenthal N; Yavin Y; Bull S; Jardine M; Pollock C; Heerspink HJL; Hansen MK, 2022, 'INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-7 PREDICTS CARDIOVASCULAR AND RENAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: THE CREDENCE TRIAL', Journal of the American College of Cardiology, 79, pp. 299 - 299, http://dx.doi.org/10.1016/s0735-1097(22)01290-6

Neuen BL; Oshima M; Perkovic V; Agarwal R; Arnott C; Bakris G; Cannon CP; Charytan DM; Edwards R; Górriz JL; Jardine MJ; Levin A; Neal B; De Nicola L; Pollock C; Rosenthal N; Wheeler DC; Mahaffey KW; Heerspink HJL, 2021, 'Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: The CREDENCE trial', European Heart Journal, 42, pp. 4891 - 4901, http://dx.doi.org/10.1093/eurheartj/ehab497

Hockham C; Kotwal S; Wilcox A; Bassi A; McGree J; Pollock C; Burrell LM; Bathla N; Kunigari M; Rathore V; John M; Lin E; Jenkins C; Ritchie A; McLachlan A; Snelling T; Jones M; Jha V; Jardine M, 2021, 'Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trial', Trials, 22, pp. 573, http://dx.doi.org/10.1186/s13063-021-05521-0

Feng KY; Li JW; Ianus J; de Zeeuw D; Fulcher GR; Pfeifer M; Matthews DR; Jardine MJ; Perkovic V; Neal B; Mahaffey KW, 2021, 'Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis', Diabetes, Obesity and Metabolism, 23, pp. 2707 - 2715, http://dx.doi.org/10.1111/dom.14525

Wong MG; Lv J; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Zhao M; Barbour S; Reich HN; Cattran D; Glassock R; Levin A; Jardine MJ; Wheeler DC; Woodward M; Billot L; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Zhang H; Perkovic V, 2021, 'The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics', American Journal of Nephrology, 52, pp. 827 - 836, http://dx.doi.org/10.1159/000519812

Young TK; Li JW; Kang A; Heerspink HJL; Hockham C; Arnott C; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine M, 2021, 'Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program', Diabetologia, 64, pp. 2402 - 2414, http://dx.doi.org/10.1007/s00125-021-05524-1

Neuen BL; Oshima M; Perkovic V; Arnott C; Bakris G; Cannon CP; Charytan DM; Jardine M; Levin A; Neal B; Pollock C; Wheeler DC; Mahaffey KW; Heerspink HJL, 2021, 'Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial', European Heart Journal, 42, pp. ehab724.2647, http://dx.doi.org/10.1093/eurheartj/ehab724.2647

Kang A; Arnold R; Gallagher M; Snelling P; Green J; Fernando M; Kiernan MC; Hand S; Grimley K; Burman J; Heath A; Rogers K; Bhattacharya A; Smyth B; Bradbury T; Hawley C; Perkovic V; Krishnan AV; Jardine MJ, 2021, 'Effect of hemodiafiltration on the progression of neuropathy with kidney failure: A randomized controlled trial', Clinical Journal of the American Society of Nephrology, 16, pp. 1365 - 1375, http://dx.doi.org/10.2215/CJN.17151120

Wang KM; Li JW; Bhalla V; Jardine MJ; Neal B; de Zeeuw D; Fulcher G; Perkovic V; Mahaffey KW; Chang TI, 2021, 'Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program', Endocrinology, Diabetes and Metabolism, 4, pp. e00247, http://dx.doi.org/10.1002/edm2.247

Tiong MK; Krishnasamy R; Smith ER; Hutchison CA; Ryan EG; Pascoe EM; Hawley CM; Hewitson TD; Jardine MJ; Roberts MA; Cho Y; Wong MG; Heath A; Nelson CL; Sen S; Mount PF; Vergara LA; Paul-Brent PA; Johnson DW; Toussaint ND, 2021, 'Effect of a medium cut-off dialyzer on protein-bound uremic toxins and mineral metabolism markers in patients on hemodialysis', Hemodialysis International, 25, pp. 322 - 332, http://dx.doi.org/10.1111/hdi.12924

Cardoza K; Kang A; Smyth B; Yi TW; Di Tanna GL; Pollock CA; De Zeeuw D; Wheeler DC; Cannon CP; Zinman B; Jardine MJ; Arnott C; Levin A; Mahaffey KW, 2021, 'Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE', DIABETES, 70, http://dx.doi.org/10.2337/db21-133-LB

Yi TW; Smyth B; Kang A; Cardoza K; Di Tanna GL; Arnott C; Pollock CA; Agarwal R; Bakris G; Cannon CP; De Zeeuw D; Heerspink HL; Levin A; Neal B; Wheeler DC; Zhang H; Zinman B; Mahaffey KW; Perkovic V; Jardine MJ, 2021, 'Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial', DIABETES, 70, http://dx.doi.org/10.2337/db21-129-LB

Liao J; Kang A; Xia C; Arnott C; Di Tanna GL; Krishnan AV; Pollock CA; Agarwal R; Bakris G; Heerspink HL; Levin A; De Zeeuw D; Neal B; Zhang H; Wheeler DC; Zinman B; Mahaffey KW; Perkovic V; Jardine MJ; Smyth B, 2021, 'The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial', DIABETES, 70, http://dx.doi.org/10.2337/db21-131-LB

Back to profile page